

## 7 Referenzen

1. Corrigan, C.J., Kay, A.: T cell/eosinophil interactions in the induction of asthma. *Eur Respir J* 9: 72-78, 1996
2. Götz, R., et al.: Neurotrophin-6 is a new member of the nerve growth factor family. *Nature* 372: 266-269, 1994
3. Lay, K.O., et al.: Cloning and expression of a novel neurotrophin, NT-7, from carp. *Mol Cell Neurosci* 11: 64-76, 1998
4. Liuzzi, A., et al.: Metabolic effects of a specific nerve growth factor (NGF) on sensory and sympathetic ganglia: enhancement of lipid biosynthesis. *J Neurochem* 12 (8): 705-708, 1965
5. Levi-Montalcini, R., et al.: The nerve growth factor 35 years later. *Science* 237 (4819): 1154-1162, 1987
6. Levi-Montalcini, R., et al.: Nerve growth factor: from neurotrophin to neurokinine. *Trends Neurosci* 19 (11): 514-520, 1996
7. Missale, C., et al.: Nerve growth factor in the anterior pituitary: Localization in mammothroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. *Proc Natl Acad Sci USA* 93: 4240-4245, 1996
8. Hoyle, G.W., et al.: Hyperinnervation of the airways in transgenic mice overexpressing nerve growth factor. *Am J Respir Cell Mol Biol* 18: 149-157, 1998
9. Dmitrieva, N., et al.: The role of nerve growth factor in a model of visceral inflammation. *Neuroscience* 78 (2): 449-459, 1997 106.
10. Sanico, A.M., et al.: Neural hyperresponsiveness and nerve growth factor in allergic rhinitis. *Int Arch Allergy Immunol* 18: 154-158, 1999
10. Sanico, A. M., et al.: Nerve Growth factor expression and release in allergic inflammatory disease of the upper airways. *Am J Respir Crit Care Med* 161: 1631-1635, 2000
11. Lindsay, R.M., Harmar, A.J.: Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. *Nature* 337: 362-364, 1989
12. Joos, G.F., Pauwels, R.A. : The bronchoconstrictor effect of sensory neuropeptides in man. *Ann NY Acad Sci* 629: 371-382, 1991
13. Cheung, D., et al.: Neutral endopeptidase activity and airway hyperresponsiveness to neurokinin A in Asthmatic subjects in vivo. *Am Rev Respir Dis* 148: 1467-1473, 1993

14. Cheung, D., et al.: Effects of inhaled substance P on airway responsiveness to methacholine in asthmatic subjects in vivo. *J Appl Physiol* 77: 1325-1332, 1994
15. Tudoric, N., et al.: Allergen inhalation challenge induces decrease of serum neutral endopeptidase (NEP) in asthmatics. *Peptides* 21: 359-364, 2000
16. De Vries, A., et al.: Nerve growth factor induces a neurokinin-1-receptor-mediated airway hyperresponsiveness in guinea pigs. *Am J Respir Crit Care Med* 159: 1541-1544, 1999
17. Heaney, L.G., et al.: Neurokinin A is the predominant tachykinin in human bronchoalveolar lavage fluid in normal and asthmatic subjects. *Thorax* 53: 357-362, 1998
18. Advenier, C., et al.: Role of tachykinins as contractile agonists of human airways in asthma. *Clin Exp Allergy* 29: 579-584, 1999
19. Lundberg, J.M.: Tachykinins, sensory nerves, and asthma-an overview. *Can J Physiol Pharmacol* 73: 908-914, 1995
20. Adcock, I.M., et al.: Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids. *J Mol Endocrinol* 11: 1-7, 1993
21. Donnerer, J., et al.: Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. *Neuroscience* 49: 693-698, 1992
22. Braun, A., et al.: Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma. *Eur J Immunol* 28: 3240-3251, 1998
23. Yamaguchi, Y., et al.: Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. *Blood* 78 (10): 2542-2547, 1991
24. Jacoby, D.B., et al.: Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. *J Clin Invest* 91: 1314-1318, 1993
25. Jacoby, D.B., et al.: Eosinophil recruitment to the airway nerves. *J Allergy Clin Immunol* 107: 211-218, 2001
26. Horigome, K., et al.: Mediator release from mast cells by nerve growth factor. *J of Biological Chemistry* 268 (20):14881-14887, 1993
27. Horigome, K., et al.: Effects of nerve growth factor on rat peritoneal mast cells. *The Journal of Biological Chemistry* 269 (4): 2695-2702, 1994

28. Yanagida, P., et al.: Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. *Blood* 86 (10): 3705-3714, 1995
29. Torcia, M., et al: Nerve growth factor is an autocrine survival factor for memory B-lymphocytes. *Cell* 85: 345-356, 1996
30. Kannan, Y., et al.: Nerve growth factor suppresses apoptosis of murine neutrophils. *Biochem Biophys Res Commun* 186: 1050-1056, 1992
31. Simone, M.D., et al. : Nerve growth factor : a survey of activity on immune and hematopoietic cells. *Hematol Oncol* 17: 1-10, 1999
32. Sawada, J., et al.: Nerve growth factor functions as a chemoattractant for mast cells through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling pathways. *Blood* 95: 2052-2058, 2000
33. Boyle, M.D., et al.: Nerve growth factor: a chemotactic factor for polymorphonuclear leucocytes in vivo. *J Immunol* 134: 564-568, 1985
34. Otten, U., et al.: Nerve growth factor induces growth and differentiation of human B lymphocytes. *Proc Natl Acad Sci USA* 86: 10059-10063, 1989
35. Burgi, B., et al.: Basophil priming by neurotrophic factors: activation through the trk receptor. *J Immunol* 157: 5582-5588, 1996
36. Robinson, D.S., et al.: Eosinophil development and bone marrow and tissue eosinophils in atopic asthma. *Int Arch Allergy Immunol* 118: 98-100, 1999
37. Seidl, K., et al.: Evidence for the participation of nerve growth factor and its low-affinity receptor (p75NTR) in the regulation of the myogenic program. *J Cell Physiol* 176: 10-21, 1998
38. Matsuda, H., et al.: Nerve growth factor promotes human hemopoietic colony growth and differentiation. *Proc Natl Acad Sci USA* 85 (17): 6508-6512, 1988
39. Li, A.K., et al.: Nerve growth factor: acceleration of the rate of wound healing in mice. *Proc Natl Acad Sci USA* 77 (7): 4379-4381, 1980
40. Asaumi, K., et al.: Expression of neurotrophins and their receptors (TRK) during fracture healing. *Bone* 26(6): 625-633, 2000
41. Leibrock, J., et al.: Molecular Cloning and expression of brain-derived neurotrophic factor. *Nature* 341 (6238): 149.152, 1989
42. Ernfors, P., et al.: Mice lacking brain-derived neurotrophic factor develop with sensory deficits. *Nature* 368 (6467): 147-150, 1994

43. Novikova, L., et al.: Effects of neurotransplants and BDNF on the survival and regeneration of injured adult spinal motoneurons. *Eur J Neurosci* 9 (12): 2774-2777, 1997
44. Hyman, C., et al.: Overlapping and distinct actions of the neurotrophins BDNF, NT-3 and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. *J Neurosci* 14 (1): 335-347, 1994
45. Stadelmann, C., et al. : BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? *Brain* 125 (Pt 1): 75-85, 2002
46. Kerschensteiner, M., et al.: Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation. *J Exp Med* 189 (5): 865-870, 1999
47. Lommatzsch, M., et al.: Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. *Am J Pathol* 155: 1183-1193, 1999
48. Braun, A., et al.: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation. *Br J Pharmacol* 141: 431-440, 2004
49. Friedman, W.J., et al.: Differential actions of neurotrophins in the locus coeruleus and basal forebrain. *Exp Neurol* 119 (1): 72-78, 1993
50. Cheka, N., et al.: Developmental regulation of BDNF and NT-3 expression by quinolinic acid in the striatum and its main connections. *Exp Neurol* 165 (1): 118-124, 2000
51. Airaksinen, M.S., et al.: Specific subtypes of cutaneous mechanoreceptors require neurotrophin-3 following peripheral target innervation. *Neuron* 16 (2): 287-295, 1996
52. Leon, A., et al.: Mast cells synthesize, store, and release nerve growth factor. *Proc Natl Acad Sci. USA* 91: 3739-3743, 1994
53. Nemoto, K., et al.: Gene expression of neurotrophins and their receptors in cultured rat vascular smooth muscle cells. *Biochemical and Biophysical Research Communications* 245: 284-288, 1998
54. Hanf, G., et al.: Modulation of nerve growth factor release from human nasal fibroblasts: possible role in airway inflammatory diseases. *J Allergy Clin Immunol* 109: 72, 2002

55. Braun, A., et al.: Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. *Am J Respir Cell Mol Biol* 21: 537-546, 1999
56. Noga, O., et al.: The production, storage, and release of the neurotrophins NGF, BDNF and NT-3 by human peripheral eosinophils in allergics and nonallergics. *Clin Exp Allergy* 33 (5): 649-654, 2003
57. Aloe, L., et al.: Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. *Proc Natl Acad Sci USA* 91: 10440-10444, 1994
58. Klein, R., et al.: The trkB tyrosin protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. *Cell* 66 (2): 395-403, 1991
59. Lambiase, A., et al.: Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. *Invest Ophthalmol Vis Sci* 39 (7): 1272-1275, 1998
60. Labouyrie, E., et al.: Distribution of NGF receptors in normal and pathologic human lymphoid tissues. *Journal of Neuroimmunology* 77: 161-173, 1997
61. Garcia-Suarez, O., et al.: Neurotrophin receptor like protein immunoreactivity in human lymph nodes. *Anat Rec* 249: 226-232, 1997
62. Ehrhard, P.B., et al.: Expression of functional trk protooncogene in human monocytes. *Proc Natl Acad Sci USA* 90: 5423-5427, 1993
63. Garcia-Suarez, O., et al.: Expression of the TrkB neurotrophin receptor by thymic macrophages. *Immunology* 94: 235-241, 1998
64. Tam, S.-Y., et al.: Expression of functional Trk A receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. *Blood* 90 (5): 1807-1820, 1997
65. Noga, O., et al.: Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils. *Clin Exp Allergy* 32: 1348-1354, 2002
66. Kaplan, D.R., Miller, F.D.: Neurotrophin signal transduction in the nervous system. *Curr Opin Neurobiol* 10 (3): 381-391, 2000
67. Oddiah, D., et al.: Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. *NeuroReport* 9: 1455-1458, 1998
68. Lambiase, A., et al.: Increased plasma levels of nerve growth factor in vernal keratoconjunctivitis and relationship to conjunctival mast cells. *Invest Ophthalmol Vis Sci* 36 (10): 2127-2132, 1995

69. Bracci Laudiero, L., et al.: Increased levels of NGF in sera of systemic lupus erythematosus patients. *NeuroReport* 4 (5): 563-565, 1993
70. Falcini, F., et al.: Increased circulating nerve growth factor is directly correlated with disease activity in juvenile chronic arthritis. *Ann Rheum Dis* 55: 745-748, 1996
71. Falcini, F., et al.: Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. *J Rheumatol* 23 (10): 1798-1802, 1996
72. Aloe, L., et al.: *Schistosoma mansoni* infection enhances the levels of NGF in the liver and hypothalamus of mice. *NeuroReport* 5 (9): 1030-1032, 1994
73. Bonini, S., et al.: Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. *Proc Natl Acad Sci USA* 93: 10955-10960, 1996
74. Virchow, J.C., et al.: Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation. *Am J respir Crit Care Med* 158: 2002-2005, 1998
75. Gleich, G.J.: The eosinophilic leucocyte: past, present and future. In: Makino, S., Fukuda, T., eds. *Eosinophils: Biological and Clinical Aspects*. Boca Raton: CRC Press: 1-10, 1993
76. Sanderson, C.J. : Interleukin-5, eosinophils, and disease. *Blood* 79 (12): 3101-3109, 1992
77. Horn, B.R., et al: Total eosinophil counts in the management of bronchial asthma. *N Engl J Med* 292 (22): 1152-1155, 1975
78. Weller, P.F., et al.: Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule1. *Proc Natl Acad Sci USA* 88 (16): 7430-7433, 1991
79. Laitinen, L.A., et al. : Leukotriene E4 and granulocytic infiltration into asthmatic airways. *Lancet* 341 (8851): 989-990, 1993
80. Spada, C.S., et al.: Leukotrienes cause eosinophil emigration into conjunctival tissue. *Prostaglandins* 31 (4) : 795-809, 1986
81. DiScipio, R.G., et al.: A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. *J Immunol* 162 (2): 1127-1136, 1999
82. Wasmoen, T.L., et al.: Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein. *J Biol Chem* 263:12559-12563, 1988

83. Gleich, G.J., et al.: Eosinophils. In: Frank, M. M., Austen K. F., Claman, H.N., Unanue, E.R., eds. *Samter's Immunologic Diseases*. Boston: Little Brown: 205-245, 1994
84. Frigas, E., et al.: Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. *Lab Invest* 42: 35-43, 1980
85. Frigas, E., et al.: Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. *Mayo Clin Proc* 56: 345-353, 1981
86. Fryer, A.D., Maclagan, J.: Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. *Br J Pharmacol* 83: 973-978, 1984
87. Lefort, J., et al.: In vivo neutralization of eosinophil major basic protein prevents hyperresponsiveness by bronchial hyperreactivity in sensitized guinea pigs. *J Clin Invest* 97: 1117-1121, 1996
88. Elbon, C.L., et al.: Pretreatment with an antibody to interleukin-5 prevents loss of pulmonary M2 muscarinic receptor function in antigen-challenged guinea pigs. *Am J Respir Cell Mol Biol* 12: 320-328, 1995
89. O'Donnell, M.C., et al.: Activation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. *J Exp Med* 157: 1981-1991, 1983
90. Moy, J.N., et al.: Noncytotoxic activation of neutrophils by eosinophil granule major basic protein: effect on superoxide anion generation and lysosomal enzyme release. *J Immunol* 145: 2626-2632, 1990
91. Rohrbach, M.S., et al.: Activation of platelets by eosinophil enzyme release. *J Immunol* 145: 2626-2632, 1990
92. Rankin, J.A., et al.: The effects of eosinophil-granule major basic protein on lung-macrophage superoxide anion generation. *J Allergy Clin Immunol* 89: 746-752, 1992
93. Kita, H., et al.: Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. *J Immunol* 154: 4749-4758, 1995
94. Maddox, D.E., et al.: Localization of a molecule immunochemically similar to eosinophil major basic protein in human placenta. *J Exp Med* 160 (1): 29-41, 1984
95. Gleich, G.J., et al.: Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. *Proc Natl Acad Sci USA* 83: 3146-3150, 1986
96. Snyder, M.R., Gleich, G.J.: Eosinophil-associated ribonucleases. In: D'Alessio, G., Riordan, J. F., eds. *Ribonucleases: Structure and Function*. New York; Academic Press: 425-444, 1997

97. Durack, D.T., et al.: Neurotoxicity of human eosinophils. *Proc Natl Acad Sci USA* 76: 1443-1447, 1979
98. Motojima, S., et al.: Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. *Am Rev Respir Dis* 139: 801-805, 1989
99. Carlson, M.G.Ch., et al.: Human eosinophil peroxidase: purification and characterization. *J Immunol* 134: 1875-1879, 1985
100. Klebanoff, S.J., et al.: The eosinophil peroxidase: Purification and biological properties. In: Mahmoud, A.A.F., Austen, K.F., eds. *The eosinophil in Health and disease*. New York: Grune & Stratton: 99-114, 1980
101. Minnicozzi, M., et al.: Eosinophil granule proteins increase microvascular macromolecular transport in the hamster cheek pouch. *J Immunol* 153: 2664-2670, 1994
102. Ackermann, S.J., et al.: Formation of Charcot-Leyden crystals by human basophils. *J Exp Med* 155 (6): 1597-1609, 1982
103. Charcot, J., Robin, C.: Observation de leukocythemie. *CR SG Mem Soc Biol* 5: 44-56. 1853
104. Leyden von, E.: Zur Erkenntnis des bronchialen Asthma. *Virchow Arch (Path Anat)* 54: 324-344, 1872
105. Hartnell, A., et al.: Fc gamma and CD11/CD18 receptor expression on normal density and low density human eosinophils. *Immunology* 69 (2): 264-270, 1990
106. Abdelilah, S.G., et al.: Molecular characterization of the low-affinity IgE receptor Fc epsilonR2/CD23 expressed by human eosinophils. *Int Immunol* 10 (4): 395-404, 1998
107. Abu Ghazaleh, R.I., et al.: IgA-induced eosinophil degranulation. *J Immunol* 142 (7): 2393-2400, 1989
108. Daffern, P.J., et al.: C3a is a chemotaxin for human eosinophils but not for neutrophils. C3a stimulation of neutrophils is secondary to eosinophil activation. *J Exp Med* 181 (6): 2119-2127, 1995
109. Zeck Kapp, G., et al.: Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. *Allergy* 50 (1): 34-47, 1995
110. Richards, I.M., et al.: Contribution of leukotriene B4 to airway inflammation and neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. *J Exp Med* 181 (6): 2119-2127, 1995



111. Underwood, D.C., et al.: Persistent airway eosinophilia after Leukotriene (LT) D<sub>4</sub> administration in the guinea pig: modulation by the LTD<sub>4</sub> receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. *Am J Respir Crit Care Med* 154 (4 Pt 1): 850-857, 1996
112. Fukuda, T., et al.: Platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils. *J Lipid Mediat* 5 (2): 145-149, 1992
113. Dobrina, A., et al.: Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. *J Clin Invest* 88 (1): 20-26, 1991
114. Dunzendorfer, S., et al.: Signaling in neuropeptide-induced migration of human eosinophils. *J Leukoc Biol* 64 (6): 828-834, 1998
115. Prin, L., et al.: Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients : absence of detectable receptor correlates with resistance to corticotherapy. *Clin Exp Immunol* 78 (3): 383-389, 1989
116. Sur, S., et al. : Allergen challenge in asthma : association of eosinophils and lymphocytes with interleukin-5. *allergy* 50 (11): 891-898, 1995
117. Luttmann, W., et al.: Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression and promotion of cellular viability. *J Immunol* 157 (4): 1678-1683, 1996
118. Pretolani, M., et al.: Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. *J Exp Med* 180: 795-805, 1994
119. Woerly, G., et al.: Expression of Th1 und Th2 immunoregulatory cytokines by human eosinophils. *Int Arch Allergy Immunol* 118: 95-97, 1999
120. Elovic, A., et al.: Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. *J Allergy Clin Immunol* 93 (5): 864-869, 1994
121. Foreman, R.C., et al.: Role of the eosinophil in protein oxidation in asthma: possible effects on proteinase/antiproteinase balance. *Int Arch Allergy Immunol* 118: 183-186, 1999
122. Zheutlin, L.M., et al.: Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. *J Immunol* 133: 2180-2185, 1984

123. Garcia Zepeda, E.A., et al.: Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. *Nat Med* 2 (4): 449-456, 1996
124. Noga, O., et al.: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. *Int Arch Immunol* 131: 46-52, 2003
125. Jardieu, P.M., Fick, R.B. : IgE-Inhibition as a therapy for allergic disease. *Int Arch Allergy Immunol* 118: 112-115, 1999
126. Iijima, M., et al.: Relationship between airway hyperreactivity and various atopic factors in bronchial asthma. *Jpn J Allergol* 34: 226-233, 1985
127. Gundel, R.H., et al.: Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in Primates. *J Appl Physiol* 68: 779-786, 1990
128. Gleich, G.J., et al.: Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. *J Clin Invest* 57: 633-640, 1976
129. Lewis, D.M., et al.: Isolation and partial characterization of a major basic protein from rat eosinophil granules. *Proc Soc Exp Biol Med* 152 : 512-515, 1976
130. Noga, O., et al.:The influence of inhalative corticosteroids on circulating nerve growth factor, brain derived neurotrophic factor and neurotrophin-3 in allergic asthmatics. *Clin Exp Allergy* 31: 1906-1912, 2001
131. Adachi, T., et al.: Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. *J Allergy Clin Immunol* 9: 207-215, 1996
132. Gleich, G.J., et al.: Glucocorticoid effects on human eosinophils. In: Schleimer, R.P., Busse, W.W., O'Byrne, P.M., eds. *Inhaled glucocorticoids and asthma: Mechanisms and clinical actions, lung biology in health and disease*. New York: Marcel Dekker, Inc., Vol. 97, Chapter 13, 279-308, 1996
133. Hagan, J.B., et al.: Inhibition of interleukin-5 mediated eosinophil viability by fluticasone 17-propionate: comparison with other glucocorticoids. *Clinical and Experimental Allergy* 28: 999-1006, 1998
134. Ohta, K., Yamashita, N.: Apoptosis of eosinophils and lymphocytes in allergic inflammation. *J Allergy Clin Immunol* 104: 14-21, 1999
135. De Vries, A., et al. : Antibodies directed against nerve growth factor inhibit the acute bronchoconstriction due to allergen challenge in guinea-pigs. *Clin Exp Allergy*, 32 (2): 325-28, 2002

136. Sullivan, P., et al. : Anti-inflammatory effect of low-dose oral theophylline in atopic asthma. *Lancet* 343 (8904): 1006-1008, 1994
137. Chung, I.Y., et al.: The downregulation of Bcl-2 expression is necessary for theophylline-induced apoptosis of eosinophils. *Cellular Immunology* 203: 95-102, 2000
138. Djukanovic, R., et al.: The effects of theophylline on mucosal inflammation in asthmatic airways : biopsy results. *Eur Respir J* 8 (5): 831-833, 1995
139. Bryant, R.E., et al.: The effect of 3'-5' cyclic adenosine monophosphate on granulocyte adhesion. *J Clin Invest* 54: 1241-1244, 1974
140. Diamant, B., et al.: Desensitization of rat mast cells by the use of theophyllin. *Agent Actions* 4 (3): 205, 1974
141. Pauwels, R., et al.: The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. *J Allergy Clin Immunol* 76: 583-590, 1985
142. Momose, T., et al.: Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. *Int Arch Allergy Immunol* 117: 138-145, 1998
143. Calhoun, W.J., et al.: Modulation of superoxyde production of alveolar macrophages and peripheral blood mononuclear cells by beta-agonists and theophylline. *J Lab Clin Med* 117: 514-522, 1991
144. Ezeamuzie, C.I.: Involvement of A3-Receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline. *Biochemical Pharmacology* 61: 1551-1559, 2001